| 摘要 |
1434486 Spiro piperidine/thiaxanthenes IMPERIAL CHEMICAL INDUSTRIES Ltd 2 Jan 1975 [4 Feb 1974] 05017/74 Heading C2C [Also in Division A5] The invention comprises compounds of formula and their pharmaceutically acceptable acid addition salts, wherein R<SP>1</SP> is H, C 1-10 alkyl, C 3-10 alkenyl, C 4-7 cycloalkyl-alkyl (optionally nuclear-substituted by C 6-10 aryl or by up to 2 C 1-3 alkyls), C 8-12 aroylalkyl (optionally nuclearsubstituted by 1-3 halogen atoms or C 1-3 alkyls) or C 2-5 hydroxyalkyl; R<SP>2</SP> ... R<SP>5</SP> are each H, halogen, OH or (up to C 5 ) alkyl, haloalkyl, alkoxy, alkylthio, alkanoyloxy or hydroxyalkyl; and A is S, SO or SO 2 . In examples, these compounds are prepared by (ii) reacting thiaxanthene with NaH/Me 2 SO and (2) reacting a 9,9-bis-(XCH 2 CH 2 )-thiaxanthene (or the S-oxide or dioxide) (Q) where X is Cl or MeSO 3 , with R<SP>1</SP>NH 2; (3) hydrolysing and decarboxylating the N-carbophenoxy compound; (4) reacting an N-cyano compound with LiAlH 4 followed by NaOH (for R<SP>1</SP>=H); (5) reducing an N - cycloalkylcarbonyl compound, (6) converting one or more of R<SP>2</SP> ... R<SP>5</SP>=MeO to HO, and HO to AcO. Starting materials and intermediates otherwise prepared are analogues of (I) where R<SP>1</SP> is benzyl; analogues of (Q) where X is OCH : CH 2 or OH, and the corresponding 9,9-unsubstituted or 9-oxo-thiaxanthenes; and the acids 2- (o-ROC 6 H 4 S)-C 6 H 4 CO 2 H where R is Me or Et and the ring containing the CO 2 H group may be further substituted. Therapeutic compositions having analgesic and in some cases sedative activity comprise compounds of the above formula. They may be administered orally, parenterally or rectally, and may contain further active ingredients (see Division A5). |
